Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Context Therapeutics Inc. CNTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.25
+109.2%

Context Therapeutics Inc. (CNTX) is a Biotechnology company in the Healthcare sector, currently trading at $2.51. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is CNTX = $5 (+109.2% upside).

Valuation: CNTX trades at a trailing Price-to-Earnings (P/E) of -6.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 434.55.

Net income is $36M (loss), growing at -36.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $112,064 against $60M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 8.52 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $68M.

Analyst outlook: 6 / 6 analysts rate CNTX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 61/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$5.25
▲ 109.16% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Context Therapeutics Inc., the average price target is $5.25, with a high forecast of $6.00, and a low forecast of $4.50.
Highest Price Target
$6.00
Average Price Target
$5.25
Lowest Price Target
$4.50

CNTX SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 61/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CNTX

✓
VALUE Pass
61/100
CNTX trades at a trailing Price-to-Earnings (P/E) of -6.8 (S&P 500 average ~25). Forward PEG 434.55 — overvalued. Trailing PEG 0.26. Analyst consensus target is $5, implying +99.2% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CNTX: +0%/yr revenue is, -36.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet CNTX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 8.52 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
CNTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 6 / 6 analysts rate CNTX as buy (100%). Analyst consensus target is $5 (+99.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.49-3.62
Volume936.59K
Avg Volume (30D)1.33M
Market Cap$230.62M
Beta (1Y)1.83
Share Statistics
EPS (TTM)-0.38
Shares Outstanding$95.19M
IPO Date2021-10-20
Employees12
CEOMartin A. Lehr
Financial Highlights & Ratios
Gross Profit$-124.66K
EBITDA$-39.7M
Net Income$-36.12M
Operating Income$-39.7M
Total Cash$66M
Total Debt$112.06K
Net Debt$-65.88M
Total Assets$68.49M
Price / Earnings (P/E)-6.6
Analyst Forecast
1Y Price Target$5.25
Target High$6.00
Target Low$4.50
Upside+109.2%
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS21077P1084

Price Chart

Track all markets on TradingView
CNTX
Context Therapeutics Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.49 52WK RANGE 3.62

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 WVE
WVE
Wave Life Sciences Ltd.
$7.59
+2.71%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$17.12
+1.18%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.56
+0.44%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 ANNX
ANNX
Annexon, Inc.
$6.35
+9.48%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message